CBIO Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-11-20 | Luo Ying | director | 3,350,897 | A-Award | A | 3,350,897 | 0.75 | 2,513,173.00 |
| 2023-10-30 | Luo Ying | director | 2,840,376 | J-Other | A | 2,840,376 | 0.00 | 0.00 |
| 2023-11-20 | Luo Ying | director | 2,262,755 | A-Award | A | 2,262,755 | 0.75 | 1,697,066.00 |
| 2023-11-20 | Ye Weiguo | officer: Chief Operating Officer | 1,665,115 | A-Award | A | 1,665,115 | 0.75 | 1,248,836.00 |
| 2023-11-20 | Ma Songjiang | director, officer: President | 4,510,047 | A-Award | A | 4,510,047 | 0.75 | 3,382,535.00 |
| 2023-11-20 | Chen Ruoyu | officer: Chief Financial Officer | 578,540 | A-Award | A | 578,540 | 0.75 | 433,905.00 |
| 2023-10-30 | GNI Group Ltd. | 10 percent owner | 64,005,887 | J-Other | A | 63,588,119 | 0.00 | 0.00 |
| 2023-11-20 | Wu Charles C | director, officer: Chief Executive Officer | 170,417 | A-Award | A | 170,417 | 0.75 | 127,813.00 |
| 2023-10-30 | Ma Songjiang | director, officer: President | 2,942,467 | I | 0 | 0.00 | 0.00 | |
| 2023-10-31 | Luo Ying | director | 1,866 | A-Award | A | 1,866 | 6.93 | 12,931.00 |
| 2023-10-31 | Eastling Thomas Wilson | director | 314,652 | A-Award | A | 314,652 | 6.93 | 2,180,538.00 |
| 2023-10-31 | Eastling Thomas Wilson | director | 1,866 | A-Award | A | 1,866 | 6.93 | 12,931.00 |
| 2023-10-31 | Parry Renate | director | 1,866 | A-Award | A | 1,866 | 6.93 | 12,931.00 |
| 2023-10-31 | Chen Ruoyu | officer: Interim CFO | 34,380 | A-Award | A | 34,380 | 6.93 | 238,253.00 |
| 2023-10-31 | USMAN NASSIM | director | 341,652 | A-Award | A | 341,652 | 6.93 | 2,367,648.00 |
| 2023-10-31 | USMAN NASSIM | director | 1,866 | A-Award | A | 1,866 | 6.93 | 12,931.00 |
| 2023-10-31 | Ying Han | director | 1,866 | A-Award | A | 1,866 | 6.93 | 12,931.00 |
| 2023-10-31 | Carmichael Gordon | director | 1,866 | A-Award | A | 1,866 | 6.93 | 12,931.00 |
| 2023-10-30 | Ma Songjiang | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Parry Renate | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Ying Han | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Carmichael Gordon | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Ye Weiguo | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Chen Ruoyu | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-30 | Wu Charles C | 0 | 0 | 0.00 | 0.00 | |||
| 2023-10-27 | GNI Group Ltd. | 10 percent owner | 8,110,300 | P-Purchase | A | 8,110,300 | 0.00 | 0.00 |
| 2023-10-27 | GNI Group Ltd. | 10 percent owner | 13,151 | P-Purchase | A | 811 | 0.00 | 0.00 |
| 2023-10-27 | GNI Group Ltd. | 10 percent owner | 6,266,521 | I | 0 | 0.00 | 0.00 | |
| 2023-10-27 | GNI Group Ltd. | 10 percent owner | 0 | I | 123,400,000 | 0.00 | 0.00 | |
| 2023-10-27 | GNI Hong Kong Ltd | 10 percent owner | 0 | J-Other | D | 5,371,304 | 46,624,376.00 | 250,433,697,306,304.00 |
| 2023-10-27 | GNI Hong Kong Ltd | 10 percent owner | 0 | J-Other | D | 10,577 | 0.00 | 0.00 |
| 2023-08-31 | Miller Seline E. | officer: SVP Finance; Interim CFO & PAO | 0 | D-Return | D | 6.5 | 0.00 | 0.00 |
| 2023-08-31 | USMAN NASSIM | director, officer: President & CEO | 0 | D-Return | D | 1.168 | 0.00 | 0.00 |
| 2023-08-31 | Hunt Andrea | director | 0 | D-Return | D | 28.228 | 0.00 | 0.00 |
| 2023-08-31 | GNI Group Ltd. | 10 percent owner | 0 | D-Return | D | 5,371.303 | 0.00 | 0.00 |
| 2023-08-31 | LAWLOR AUGUSTINE | director | 0 | D-Return | D | 24.215 | 0.00 | 0.00 |
| 2022-12-26 | Eastling Thomas Wilson | None | 0 | None | None | 0.00 | ||
| 2022-12-26 | Eastling Thomas Wilson | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2022-12-26 | GNI Group Ltd. | director | None | D | 105,770,000 | 0.00 | 0.00 | |
| 2022-12-26 | GNI Group Ltd. | director | 5,371,304 | D | 0 | 0.00 | 0.00 | |
| 2022-12-26 | GNI Group Ltd. | director | 895,217 | D | 0 | 0.00 | 0.00 | |
| 2022-12-26 | Luo Ying | None | 0 | None | None | 0.00 | ||
| 2022-12-26 | Luo Ying | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2022-08-09 | USMAN NASSIM | officer: President & CEO | 24,541 | P-Purchase | A | 3,250 | 0.47 | 1,528.00 |
| 2022-08-09 | Miller Seline E. | officer: SVP Finance; Interim CFO & PAO | 6,500 | P-Purchase | A | 3,250 | 0.47 | 1,528.00 |
| 2022-08-09 | Blouse Grant E. | officer: Chief Scientific Officer | 9,417 | P-Purchase | A | 3,250 | 0.47 | 1,528.00 |
| 2022-02-11 | Miller Seline E. | officer: SVP Finance; Interim CFO & PAO | 107,500 | A-Award | A | 107,500 | 0.52 | 55,900.00 |
| 2022-02-11 | Blouse Grant E. | officer: Chief Scientific Officer | 200,000 | A-Award | A | 200,000 | 0.52 | 104,000.00 |
| 2022-02-09 | USMAN NASSIM | director, officer: President & CEO | 21,291 | P-Purchase | A | 3,250 | 0.46 | 1,495.00 |
| 2022-02-09 | Miller Seline E. | officer: SVP Finance; Interim CFO & PAO | 3,250 | P-Purchase | A | 3,250 | 0.46 | 1,495.00 |
| 2022-02-09 | Blouse Grant E. | officer: Chief Scientific Officer | 6,167 | P-Purchase | A | 3,250 | 0.46 | 1,495.00 |
| 2022-01-07 | Williams Eddie | director | 34,804 | A-Award | A | 12,308 | 0.00 | 0.00 |
| 2022-01-07 | Ling Geoffrey M.D. | director | 31,790 | A-Award | A | 12,855 | 0.00 | 0.00 |
| 2022-01-07 | Hunt Andrea | director | 28,228 | A-Award | A | 7,521 | 0.00 | 0.00 |
| 2021-10-13 | Miller Seline E. | officer: SVP Finance; Interim CFO & PAO | 0 | D | 16,000 | 4.81 | 76,960.00 | |
| 2021-10-01 | Williams Eddie | director | 22,496 | A-Award | A | 2,980 | 0.00 | 0.00 |
| 2021-10-01 | Ling Geoffrey M.D. | director | 18,935 | A-Award | A | 2,858 | 0.00 | 0.00 |
| 2021-10-01 | LAWLOR AUGUSTINE | director | 24,573 | A-Award | A | 5,839 | 0.00 | 0.00 |
| 2021-10-01 | Hunt Andrea | director | 20,707 | A-Award | A | 1,824 | 0.00 | 0.00 |
| 2021-10-01 | DESOUZA ERROL B | director | 29,801 | A-Award | A | 3,588 | 0.00 | 0.00 |
| 2021-09-09 | JEW JEANNE Y | director | 28,000 | A-Award | A | 28,000 | 4.38 | 122,640.00 |
| 2021-09-09 | JEW JEANNE Y | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2021-08-09 | USMAN NASSIM | director, officer: President & CEO | 18,041 | P-Purchase | A | 867 | 3.62 | 3,139.00 |
| 2021-08-09 | Levy Howard | officer: Chief Medical Officer | 639 | P-Purchase | A | 639 | 3.62 | 2,313.00 |
| 2021-08-09 | Blouse Grant E. | officer: Chief Scientific Officer | 2,917 | P-Purchase | A | 1,163 | 3.62 | 4,210.00 |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 1,754 | D | 0 | 0.00 | 0.00 | |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 0 | D | 30,000 | 12.21 | 366,300.00 | |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 0 | D | 10,000 | 9.68 | 96,800.00 | |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 0 | D | 18,000 | 7.97 | 143,460.00 | |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 0 | D | 35,000 | 6.85 | 239,750.00 | |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 0 | D | 38,500 | 5.89 | 226,765.00 | |
| 2021-07-12 | Blouse Grant E. | officer: Chief Scientific Officer | 0 | D | 25,000 | 4.33 | 108,250.00 | |
| 2021-07-01 | Williams Eddie | director | 19,516 | A-Award | A | 1,414 | 0.00 | 0.00 |
| 2021-06-09 | Williams Eddie | director | 14,000 | A-Award | A | 14,000 | 4.55 | 63,700.00 |
| 2021-06-09 | TETLOW SHARON | director | 14,000 | A-Award | A | 14,000 | 4.55 | 63,700.00 |
| 2021-07-01 | Ling Geoffrey M.D. | director | 16,077 | A-Award | A | 2,713 | 0.00 | 0.00 |
| 2021-06-09 | Ling Geoffrey M.D. | director | 14,000 | A-Award | A | 14,000 | 4.55 | 63,700.00 |
| 2021-07-01 | LAWLOR AUGUSTINE | director | 18,734 | A-Award | A | 5,542 | 0.00 | 0.00 |
| 2021-06-09 | LAWLOR AUGUSTINE | director | 14,000 | A-Award | A | 14,000 | 4.55 | 63,700.00 |
| 2021-07-01 | Hunt Andrea | director | 18,883 | A-Award | A | 2,886 | 0.00 | 0.00 |
| 2021-06-09 | Hunt Andrea | director | 14,000 | A-Award | A | 14,000 | 4.55 | 63,700.00 |
| 2021-07-01 | DESOUZA ERROL B | director | 26,213 | A-Award | A | 3,406 | 0.00 | 0.00 |
| 2021-06-09 | DESOUZA ERROL B | director | 14,000 | A-Award | A | 14,000 | 4.55 | 63,700.00 |
| 2021-02-08 | USMAN NASSIM | director, officer: President & CEO | 140,000 | A-Award | A | 140,000 | 5.89 | 824,600.00 |
| 2021-02-08 | Musil Clinton | officer: Chief Financial Officer | 54,000 | A-Award | A | 54,000 | 5.89 | 318,060.00 |
| 2021-02-08 | Levy Howard | officer: Chief Medical Officer | 25,000 | A-Award | A | 25,000 | 5.89 | 147,250.00 |
| 2021-04-05 | USMAN NASSIM | director, officer: President & CEO | 259,783 | M-Exempt | D | 5,000 | 4.63 | 23,150.00 |
| 2021-04-05 | USMAN NASSIM | director, officer: President & CEO | 17,174 | M-Exempt | A | 5,000 | 4.63 | 23,150.00 |
| 2021-04-01 | Williams Eddie | director | 18,102 | A-Award | A | 1,215 | 0.00 | 0.00 |
| 2021-04-01 | Ling Geoffrey M.D. | director | 13,364 | A-Award | A | 2,331 | 0.00 | 0.00 |
| 2021-04-01 | LAWLOR AUGUSTINE | director | 13,192 | A-Award | A | 4,761 | 0.00 | 0.00 |
| 2021-04-01 | Hunt Andrea | director | 15,997 | A-Award | A | 2,480 | 0.00 | 0.00 |
| 2021-04-01 | DESOUZA ERROL B | director | 22,807 | A-Award | A | 2,926 | 0.00 | 0.00 |
| 2021-02-09 | USMAN NASSIM | director, officer: President & CEO | 12,174 | P-Purchase | A | 582 | 4.81 | 2,799.00 |
| 2021-02-09 | Levy Howard | officer: Chief Medical Officer | 23,390 | P-Purchase | A | 1,670 | 4.81 | 8,033.00 |
| 2021-02-08 | USMAN NASSIM | director, officer: President & CEO | 140,000 | A-Award | A | 140,000 | 5.89 | 824,600.00 |
| 2021-02-08 | Musil Clinton | officer: Chief Financial Officer | 54,000 | A-Award | A | 54,000 | 5.89 | 318,060.00 |
| 2021-02-08 | Levy Howard | officer: Chief Medical Officer | 25,000 | A-Award | A | 25,000 | 5.89 | 147,250.00 |
| 2021-01-05 | Williams Eddie | director | 16,887 | A-Award | A | 940 | 0.00 | 0.00 |
| 2021-01-05 | Ling Geoffrey M.D. | director | 11,033 | A-Award | A | 1,782 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
